This company listing is no longer active
Resumen acción 9CX
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney functions.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de Cell MedX Corp.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.093 |
| 52 Week High | US$0.17 |
| 52 Week Low | US$0.093 |
| Beta | 0.74 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -46.45% |
| 3 Year Change | -80.82% |
| 5 Year Change | -59.52% |
| Change since IPO | -81.30% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 9CX | DE Medical Equipment | Mercado DE | |
|---|---|---|---|
| 7D | 0% | -3.0% | -0.4% |
| 1Y | -46.4% | -2.8% | 3.4% |
Rentabilidad frente al sector: 9CX underperformed the German Medical Equipment industry which returned -27.3% over the past year.
Rentabilidad vs. Mercado: 9CX underperformed the German Market which returned -17.8% over the past year.
Volatilidad de los precios
| 9CX volatility | |
|---|---|
| 9CX Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Precio estable de las acciones: 9CX has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine 9CX's volatility change over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2010 | n/a | Dwayne Yaretz | cellmedx.com |
Resumen de fundamentos de Cell MedX Corp.
| Estadísticas fundamentales de 9CX | |
|---|---|
| Capitalización bursátil | €6.62m |
| Beneficios(TTM) | -€886.53k |
| Ingresos (TTM) | €2.37k |
3,467x
Ratio precio-ventas (PS)-7.5x
Ratio precio-beneficio (PE)¿Está 9CX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 9CX | |
|---|---|
| Ingresos | US$2.34k |
| Coste de los ingresos | US$43.24k |
| Beneficio bruto | -US$40.90k |
| Otros gastos | US$835.21k |
| Beneficios | -US$876.11k |
Últimos beneficios comunicados
Feb 28, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.014 |
| Margen bruto | -1,747.91% |
| Margen de beneficio neto | -37,440.51% |
| Ratio deuda/patrimonio | -28.3% |
¿Cómo se ha desempeñado 9CX a largo plazo?
Ver rendimiento histórico y comparativa